GENITOURINARY CANCERS

>

Latest News

177Lu-PSMA-I&T Shows PFS Benefit in mCRPC
177Lu-PSMA-I&T Shows PFS Benefit in mCRPC

November 18th 2024

The ECLIPSE trial, a pivotal, phase 3, multi-center, open-label, randomized clinical study, has met its primary end point in metastatic castration-resistant prostate cancer.

Novel immunotherapy FK-PC101 Explored in Prostate Cancer Trial
Novel immunotherapy FK-PC101 Explored in Prostate Cancer Trial

November 18th 2024

FDA Approves IND for AS1986NS, a New Approach in Prostate Cancer Research
FDA Approves IND for AS1986NS, a New Approach in Prostate Cancer Research

November 15th 2024

Real-World Survival Outcomes in mCSPC: Comparison of Apalutamide and Abiraterone
Real-World Survival Outcomes in mCSPC: Comparison of Apalutamide and Abiraterone

November 11th 2024

Apalutamide Outperforms Enzalutamide in mCSPC Survival
Apalutamide Outperforms Enzalutamide in mCSPC Survival

November 8th 2024

Latest CME Events & Activities

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

41st Annual CFS®: Innovative Cancer Therapy for Tomorrow

View More

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management

View More

More News

FDA Approves Radium-223 for Advanced Prostate Cancer

FDA Approves Radium-223 for Advanced Prostate Cancer

Staff Writer
May 15th 2013

Radium RA 223 dichloride has been approved by the FDA for the treatment of symptomatic metastatic castration-resistant prostate cancer (mCRPC) that has spread to the bones but not to any other organs.

Read More

Using Radium-223 Plus Docetaxel in Patients With Bone Metastasis From CRPC

Using Radium-223 Plus Docetaxel in Patients With Bone Metastasis From CRPC

Michael J. Morris, MD
May 15th 2013

Michael J. Morris, MD, discusses an ongoing phase I/IIa study looking at radium-223 with docetaxel in patients with bone metastasis from castration-resistant prostate cancer.

Watch

Utilizing CTCs in Solid Tumors

Utilizing CTCs in Solid Tumors

Leonard G. Gomella, MD
May 10th 2013

Leonard G. Gomella, MD, from the Kimmel Cancer Center, discusses the utilization of circulating tumor cells in patients with solid tumors.

Watch

Findings From the COU-AA-302 Trial

Findings From the COU-AA-302 Trial

Howard I. Scher, MD
May 8th 2013

Howard I. Scher, MD, from the Memorial Sloan-Kettering Cancer Center, discusses an updated analysis of the COU-AA-302 trial.

Watch

The Role of Corticosteroids in Treatment Sequencing

The Role of Corticosteroids in Treatment Sequencing

William K. Oh, MD
April 10th 2013

William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses sequencing treatment in patients with metastatic castration resistant prostate cancer.

Watch

<1
...
333435363738>